Nutriband Inc. Advances Abuse-Deterrent Drug Delivery with AVERSA Technology
Nutriband Inc. is pioneering in the development of abuse-deterrent transdermal patches, aiming to address critical public health needs with its AVERSA Fentanyl and Buprenorphine candidates.
Nutriband Inc. (NASDAQ: NTRB) is making significant strides in the pharmaceutical industry with its innovative abuse-deterrent drug delivery system. The company's AVERSA technology is at the heart of its development pipeline, featuring the AVERSA Fentanyl patch and AVERSA Buprenorphine candidates. These products are designed to combat the abuse and misuse of transdermal patches, a pressing public health concern.
The AVERSA Fentanyl patch, potentially the first of its kind, could achieve peak annual U.S. sales between $80 to $200 million. Similarly, the AVERSA Buprenorphine candidate is projected to reach peak U.S. sales of $70 to $130 million upon approval. Both products leverage Nutriband's scalable platform, which is on track for global patent protection, marking a significant advancement in the fight against drug abuse and accidental exposure.
For more information on Nutriband's developments, visit https://ibn.fm/8PgtJ and to stay updated on Nutriband Inc., check their newsroom at https://ibn.fm/NTRB.